U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H14N2O6S3.2Na
Molecular Weight 448.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE SODIUM

SMILES

[Na+].[Na+].[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS([O-])=O)C=C2

InChI

InChIKey=AZBNFLZFSZDPQF-UHFFFAOYSA-L
InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI

Description

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

1947
99
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Primary
Approved
8429
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Primary
Approved
8429
DIASONE SODIUM

Approved Use

Unknown

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
REVIEW
https://doi.org/10.1016/S0099-5428(08)60377-9
330 mg single, oral
dose: 330 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DAPSONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Nausea, Weakness...
Other AEs:
Nausea
Weakness
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Malaise...
Other AEs:
Malaise
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Disc. AE: Hemolytic anemia, Methemoglobinemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia
Methemoglobinemia
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Disc. AE: Erythema facial, Erythema...
AEs leading to
discontinuation/dose reduction:
Erythema facial
Erythema
Furunculosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
AEs

AEs

AESignificanceDosePopulation
Nausea
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Weakness
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Malaise
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Hemolytic anemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Methemoglobinemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Erythema facial Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Erythema Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Furunculosis Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Sourcing

Sourcing

Vendor/AggregatorIDURL
AAA Chemistry
AR-1A9274
ABI Chem
AC1L1K5Q
ABI Chem
AC1Q6YP0
BOC Sciences
144-75-2
ChemTik
CTK4C4202
Compound Cloud
5351
Compound Cloud
8954
Kingston Chemistry
KST-1A1474
MuseChem
M069826
NCI Plated 2007
27222
NovoSeek
5351
ZINC
ZINC000018268128
http://zinc15.docking.org/substances/ZINC000018268128
eMolecules
260190822
PubMed

PubMed

TitleDatePubMed
Avoid, attack or do both? Behavioral and physiological adaptations in natural enemies faced with novel hosts.
2005 Nov 4
Diastereomerically and enantiomerically pure 2,3-disubstituted pyrrolidines from 2,3-aziridin-1-ols using a sulfoxonium ylide: a one-carbon homologative relay ring expansion.
2007 Feb 21
Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus.
2008 Apr 20

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
SULFOXONE SODIUM
MI   ORANGE BOOK  
Common Name English
DIASONE SODIUM
Brand Name English
ALDESULPHONE SODIUM
Common Name English
NSC-27222
Code English
SULFOXONE SODIUM [ORANGE BOOK]
Common Name English
ALDESULFONE SODIUM [MART.]
Common Name English
DISODIUM (SULFONYLBIS(P-PHENYLENEIMINO))DIMETHANESULFINATE
Common Name English
SULFOXONE SODIUM [MI]
Common Name English
Aldesulfone sodium [WHO-DD]
Common Name English
METHANESULFINIC ACID, (SULFONYLBIS(1,4-PHENYLENEIMINO))BIS-, DISODIUM SALT
Common Name English
ALDESULFONE SODIUM
INN   MART.   WHO-DD  
INN  
Official Name English
aldesulfone sodium [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
WHO-ATC J04BA03
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
Code System Code Type Description
WIKIPEDIA
ALDESULFONE SODIUM
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
DRUG BANK
DB01145
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
MERCK INDEX
m10368
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY Merck Index
SMS_ID
100000087868
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
NSC
27222
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
EVMPD
SUB05304MIG
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL1570
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
PUBCHEM
8954
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
INN
971
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
MESH
C036115
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
CAS
144-75-2
Created by admin on Fri Dec 15 15:01:53 GMT 2023 , Edited by admin on Fri Dec 15 15:01:53 GMT 2023
PRIMARY
NCI_THESAURUS
C66574
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID9023623
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
FDA UNII
57OWB0Q221
Created by admin on Fri Dec 15 15:01:54 GMT 2023 , Edited by admin on Fri Dec 15 15:01:54 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of SULFOXONE
SUBSTANCE RECORD
Structure of SULFOXONE SODIUM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966